guest ::
| Home > Publications database > Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. > print |
| Home > Publications database > Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. > print |
| 001 | 125705 | ||
| 005 | 20240303002508.0 | ||
| 024 | 7 | _ | |a 10.2217/imt-2016-0083 |2 doi |
| 024 | 7 | _ | |a pmid:27485076 |2 pmid |
| 024 | 7 | _ | |a 1750-743X |2 ISSN |
| 024 | 7 | _ | |a 1750-7448 |2 ISSN |
| 024 | 7 | _ | |a altmetric:17890435 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2017-01831 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Dick, J. |b 0 |
| 245 | _ | _ | |a Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. |
| 260 | _ | _ | |a London |c 2016 |b Future Medicine Ltd |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1522048647_13615 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation.In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data.A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit.Changes in LDH level and side effects correlate with response to therapy and survival. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a Antibodies, Monoclonal |2 NLM Chemicals |
| 650 | _ | 7 | |a Biomarkers, Pharmacological |2 NLM Chemicals |
| 650 | _ | 7 | |a CTLA-4 Antigen |2 NLM Chemicals |
| 650 | _ | 7 | |a ipilimumab |0 6T8C155666 |2 NLM Chemicals |
| 650 | _ | 7 | |a C-Reactive Protein |0 9007-41-4 |2 NLM Chemicals |
| 650 | _ | 7 | |a L-Lactate Dehydrogenase |0 EC 1.1.1.27 |2 NLM Chemicals |
| 700 | 1 | _ | |a Lang, N. |b 1 |
| 700 | 1 | _ | |a Slynko, A. |0 P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8 |b 2 |u dkfz |
| 700 | 1 | _ | |a Kopp-Schneider, A. |0 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |b 3 |u dkfz |
| 700 | 1 | _ | |a Schulz, C. |b 4 |
| 700 | 1 | _ | |a Dimitrakopoulou-Strauss, A. |0 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992 |b 5 |u dkfz |
| 700 | 1 | _ | |a Enk, A. H. |b 6 |
| 700 | 1 | _ | |a Hassel, J. C. |0 P:(DE-HGF)0 |b 7 |
| 773 | _ | _ | |a 10.2217/imt-2016-0083 |g Vol. 8, no. 9, p. 1033 - 1044 |0 PERI:(DE-600)2495964-9 |n 9 |p 1033 - 1044 |t Immunotherapy |v 8 |y 2016 |x 1750-7448 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:125705 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)4169c43af2de6fae487c89fc2e7cfaa8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)bb6a7a70f976eb8df1769944bf913596 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b IMMUNOTHERAPY-UK : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l Biostatistik |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E060-20160331 |k E060 |l KKE Nuklearmedizin |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|